19th Nov 2007 12:00
AGI Therapeutics plc19 November 2007 AGI Therapeutics to present at 19th Annual Piper Jaffray Health Care Conference in New York -- 1.30 p.m., Tuesday 27 November, 2007 -- Dublin, Ireland, November 19th 2007 - AGI Therapeutics plc ("AGI" or the"Company") (AIM, IEX: AGI), the speciality pharmaceutical company focused ongastrointestinal drug products, today announces that the Company's ChiefExecutive Officer, Dr. John Devane, will make a presentation at the 19th AnnualPiper Jaffray Health Care Conference in New York. Dr. Devane will deliver his presentation on Tuesday 27 November 2007 at 1.30p.m. EDT (5.30 p.m. UKT). Investors may access an audio webcast of thepresentation at http://www.piperjaffray.com/conferences. A copy of the presentation will be available after the event on the AGI websiteat www.agitherapeutics.com under the "Investors: Publications" tab. For further information please contact: AGI Therapeutics plc Tel: +353 1 449 3254David Kelly, Chief Financial Officer Financial Dynamics - UK Tel: +44 (0) 20 7831 3113Deborah Scott/Lara Mott Piper Jaffray Limited Tel: +44 (0) 20 3142 8700Neil MackisonWill Carnwath About AGI Therapeutics plc AGI (the company) is a specialty pharmaceutical company which is focused on thedevelopment and commercialisation of differentiated drug products forgastrointestinal (GI) diseases and disorders. AGI's common shares are listed onthe Alternative Investment Market of the London Stock Exchange (AIM) and on theIrish Enterprise Exchange of the Irish Stock Market (IEX) as AGI. The company has a portfolio of product candidates derived from its KnownMolecular Entity (KME) approach to drug re-profiling and development. RezularTM,AGI's lead product, is in Phase III clinical trials for the treatment of IBS-D. About RezularTM (AGI-003) Rezular (AGI-003) is an orally administered triple-action intestinal regulator,a first-in-class mechanism for the treatment of IBS-D. Rezular containsarverapamil, a single enantiomer moiety of the racemic drug verapamil. Unlikethe currently available commercial forms of racemic verapamil (a mixture of twoenantiomers), Rezular shows a dominant activity in treating the symptoms ofIBS-D without the traditional cardiovascular actions of the racemic drug. Theefficacy and safety of Rezular in IBS patients has already been established in aPhase II trial, the preliminary results of which were reported by the Company in2006. About IBS-D Irritable bowel syndrome (IBS) is a functional disorder that comprises a clusterof gastrointestinal symptoms which are likely to be life long and which affectbetween 10% and 20% of the population in developed markets. IBS remains themost common diagnosis made by gastroenterologists and can lead to a substantialreduction in patients' quality of life, accompanied by considerablesocio-economic and psychological consequences. Altered intestinal motility is amajor component of IBS and patients are diagnosed and sub-typed according totheir predominant symptom of bowel disturbance. Diarrhoea-predominant irritablebowel syndrome (IBS-D) is estimated to occur in one-third of all IBS patients.IBS-D represents a significant unmet medical need as there are currently fewsafe and effective therapeutic options available to these patients. For further information please see www.agitherapeutics.com This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Potentially Ai